[登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > 2-Cl-IB-MECA
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
2-Cl-IB-MECA
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
2-Cl-IB-MECA图片
CAS NO:163042-96-4
包装与价格：
包装价格(元)
10mM (in 1mL DMSO)电议
2mg电议
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
2-Cl-IB-MECA (CF-102) 是一种选择性 A3 腺苷受体 (A3AR) 激动剂 (Ki=0.33 nM)。 2-Cl-IB-MECA 的选择性分别比 A1 和 A2A 受体高 2500 倍和 1400 倍。
Cas No.163042-96-4
别名CF-102; 2-Cl-IB-MECA
化学名(2S,3S,4R,5R)-5-(2-chloro-6-((3-iodobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy-N-methyltetrahydrofuran-2-carboxamide
Canonical SMILESIC1=CC(CNC(N=C(N=C23)Cl)=C3N=CN2[C@@H]([C@@H]4O)O[C@H](C(NC)=O)[C@H]4O)=CC=C1
分子式C18H18ClIN6O4
分子量544.74
溶解度≥ 54.5mg/mL in DMSO
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Namodenoson (CF-102) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively.

In human ADF cells of astroglial lineage, 100 nM Namodenoson (2-Cl-IB-MECA) caused a marked reorganization of the cytoskeleton, with appearance of stress fibres and numerous cell protrusions. High concentrations of Namodenoson (2-Cl-IB-MECA) directly cause influx of Ca2+[2].

Intravenous administration of 200 μg/kg Namodenoson (2-Cl-IB-MECA) resulted in a short-lasting hypotension, which was accompanied by a 50-100-fold increase in plasma histamine concentrations. Administration of a second dose of Namodenoson (2-Cl-IB-MECA) did not elicit any hemodynamic effects[1].

References:
[1]. Van Schaick EA et al. Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. Eur J Pharmacol. 1996 Jul 25;308(3):311-4.
[2]. Jacobson KA et al. Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci. 1998 May;19(5):184-91.